KR102641846B1 - 메틸-CpG 결합 단백질 2를 암호화하는 재조합 아데노-관련 바이러스의 경막 내 전달 - Google Patents

메틸-CpG 결합 단백질 2를 암호화하는 재조합 아데노-관련 바이러스의 경막 내 전달 Download PDF

Info

Publication number
KR102641846B1
KR102641846B1 KR1020197017104A KR20197017104A KR102641846B1 KR 102641846 B1 KR102641846 B1 KR 102641846B1 KR 1020197017104 A KR1020197017104 A KR 1020197017104A KR 20197017104 A KR20197017104 A KR 20197017104A KR 102641846 B1 KR102641846 B1 KR 102641846B1
Authority
KR
South Korea
Prior art keywords
mecp2
raav
vector
raav vector
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197017104A
Other languages
English (en)
Korean (ko)
Other versions
KR20190126047A (ko
Inventor
케빈 포우스트
브라이언 케이. 카스파
Original Assignee
네이션와이드 칠드런스 하스피탈 인코포레이티드
오하이오 스테이트 이노베이션 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 네이션와이드 칠드런스 하스피탈 인코포레이티드, 오하이오 스테이트 이노베이션 파운데이션 filed Critical 네이션와이드 칠드런스 하스피탈 인코포레이티드
Publication of KR20190126047A publication Critical patent/KR20190126047A/ko
Application granted granted Critical
Publication of KR102641846B1 publication Critical patent/KR102641846B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
KR1020197017104A 2016-11-17 2017-11-17 메틸-CpG 결합 단백질 2를 암호화하는 재조합 아데노-관련 바이러스의 경막 내 전달 Active KR102641846B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423618P 2016-11-17 2016-11-17
US62/423,618 2016-11-17
PCT/US2017/062371 WO2018094251A1 (en) 2016-11-17 2017-11-17 Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2

Publications (2)

Publication Number Publication Date
KR20190126047A KR20190126047A (ko) 2019-11-08
KR102641846B1 true KR102641846B1 (ko) 2024-02-27

Family

ID=62145776

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197017104A Active KR102641846B1 (ko) 2016-11-17 2017-11-17 메틸-CpG 결합 단백질 2를 암호화하는 재조합 아데노-관련 바이러스의 경막 내 전달

Country Status (15)

Country Link
US (3) US11583564B2 (enExample)
EP (1) EP3541429A4 (enExample)
JP (3) JP7106534B2 (enExample)
KR (1) KR102641846B1 (enExample)
CN (2) CN110325219B (enExample)
AU (2) AU2017362491B2 (enExample)
BR (1) BR112019009834B1 (enExample)
CA (1) CA3044291A1 (enExample)
CL (1) CL2019001354A1 (enExample)
IL (2) IL322146A (enExample)
MA (1) MA46863A (enExample)
MX (1) MX2019005874A (enExample)
SA (1) SA519401806B1 (enExample)
SG (1) SG10202105090WA (enExample)
WO (1) WO2018094251A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3541429A4 (en) * 2016-11-17 2020-08-12 Nationwide Children's Hospital, Inc. INTRATHECAL ADMINISTRATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS CODING FOR METHYL-CPG-BINDING PROTEIN 2
MX2020004830A (es) 2017-11-08 2020-11-11 Avexis Inc Medios y metodo para preparar vectores virales y usos de los mismos.
CN120718958A (zh) 2018-06-08 2025-09-30 诺华股份有限公司 用于测量药物产品效力的基于细胞的测定
KR20210124300A (ko) * 2019-02-04 2021-10-14 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 Cln3 폴리뉴클레오티드의 아데노-관련 바이러스 전달
EP4045662A1 (en) * 2019-10-18 2022-08-24 Research Institute at Nationwide Children's Hospital Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene
AU2020385387A1 (en) * 2019-11-22 2022-06-02 Fondazione Irccs Ca' Granda Ospedale Maggiore Foliclinico Materials and methods for treatment of disorders associated with the IGHMBP2 gene
EP4323010A1 (en) 2021-04-13 2024-02-21 Research Institute at Nationwide Children's Hospital Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery
WO2024235164A1 (zh) * 2023-05-15 2024-11-21 上海金珂博生物技术有限公司 一种Rett综合症的基因治疗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098565A1 (en) * 2004-02-17 2009-04-16 The Hospital For Sick Children MeCP2E1 gene
US20130225666A1 (en) * 2008-12-19 2013-08-29 Nationwide Children's Hospital, Inc. Delivery of polynucleotides using recombinant aav9
WO2016100575A1 (en) * 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1995013392A1 (en) 1993-11-09 1995-05-18 Medical College Of Ohio Stable cell lines capable of expressing the adeno-associated virus replication gene
JPH09509564A (ja) 1993-11-09 1997-09-30 ターゲテッド ジェネティックス コーポレイション 高力価組換えａａｖベクターの生成
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
RU2273645C9 (ru) 1994-08-17 2006-11-27 Дзе Рокефеллер Юниверсити Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
EP0796339A1 (en) 1994-12-06 1997-09-24 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたａａｖベクター
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
WO1998009657A2 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Method for recombinant adeno-associated virus-directed gene therapy
CA2682108C (en) 1997-09-05 2013-12-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
GB9916702D0 (en) 1999-07-16 1999-09-15 Cantab Pharma Res Virus vectors and preparations and their use
WO2001083692A2 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
ES2526341T3 (es) 2001-12-17 2015-01-09 The Trustees Of The University Of Pennsylvania Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP3632472A1 (en) * 2006-10-03 2020-04-08 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
EP2240581B1 (en) 2008-01-15 2016-05-11 AbbVie Inc. Improved mammalian expression vectors and uses thereof
US20090246768A1 (en) 2008-02-15 2009-10-01 Sawalha Amr H Predicting and Diagnosing Patients With Autoimmune Disease
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
JP6202701B2 (ja) 2014-03-21 2017-09-27 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及びプログラム
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
EP3541429A4 (en) * 2016-11-17 2020-08-12 Nationwide Children's Hospital, Inc. INTRATHECAL ADMINISTRATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS CODING FOR METHYL-CPG-BINDING PROTEIN 2
AU2018281145A1 (en) * 2017-06-06 2020-01-02 University Of Massachusetts Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098565A1 (en) * 2004-02-17 2009-04-16 The Hospital For Sick Children MeCP2E1 gene
JP2016027799A (ja) 2004-02-17 2016-02-25 ザ ホスピタル フォー シック チルドレン Ｍｅｃｐ２ｅ１遺伝子
US20130225666A1 (en) * 2008-12-19 2013-08-29 Nationwide Children's Hospital, Inc. Delivery of polynucleotides using recombinant aav9
WO2016100575A1 (en) * 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Human Molecular Genetics. 2005. Vol.14, No.23, pp.3709-3722.
Molecular Therapy. 2013. Vol.21, No.1, pp.18-30.*

Also Published As

Publication number Publication date
JP2022137210A (ja) 2022-09-21
AU2017362491A1 (en) 2019-06-06
RU2019118300A3 (enExample) 2021-01-11
BR112019009834B1 (pt) 2022-05-17
CN110325219B (zh) 2024-03-26
MX2019005874A (es) 2020-02-07
SG10202105090WA (en) 2021-06-29
EP3541429A1 (en) 2019-09-25
EP3541429A4 (en) 2020-08-12
US20230321164A1 (en) 2023-10-12
US12357663B2 (en) 2025-07-15
IL266678B1 (en) 2025-08-01
CL2019001354A1 (es) 2019-09-13
JP2024045289A (ja) 2024-04-02
US20200179467A1 (en) 2020-06-11
KR20190126047A (ko) 2019-11-08
CA3044291A1 (en) 2018-05-24
AU2023202598A1 (en) 2023-07-20
AU2017362491B2 (en) 2023-02-02
IL322146A (en) 2025-09-01
JP2020503265A (ja) 2020-01-30
MA46863A (fr) 2019-09-25
SA519401806B1 (ar) 2023-03-08
CN110325219A (zh) 2019-10-11
IL266678A (en) 2019-07-31
CN118490845A (zh) 2024-08-16
US11583564B2 (en) 2023-02-21
WO2018094251A1 (en) 2018-05-24
BR112019009834A2 (pt) 2019-10-08
JP7106534B2 (ja) 2022-07-26
RU2019118300A (ru) 2020-12-17
IL266678B2 (en) 2025-12-01
US20250312400A1 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
KR102641846B1 (ko) 메틸-CpG 결합 단백질 2를 암호화하는 재조합 아데노-관련 바이러스의 경막 내 전달
US20220125952A1 (en) Delivery of polynucleotides using recombinant aav9
JP6397391B2 (ja) 神経変性障害のための遺伝子治療
JP2023144087A (ja) 組換えＧｌｕｔ１アデノ随伴ウイルスベクターコンストラクトおよびＧｌｕｔ１発現を回復させる方法
US9415121B2 (en) Delivery of MECP2 polynucleotide using recombinant AAV9
US20220202960A1 (en) Compositions useful in treatment of rett syndrome
JP2025138648A (ja) Ｃｌｎ３ポリヌクレオチドのアデノ随伴ウイルス送達
RU2788084C2 (ru) Интратекальная доставка рекомбинантного аденоассоциированного вируса, кодирующего метил-cpg-связывающий белок 2
NZ794471A (en) Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2
US20230210941A1 (en) Compositions useful in treatment of krabbe disease
WO2022170038A1 (en) Adeno-associated virus delivery of cln3 polynucleotide
CA2978917C (en) Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
CN116033915A (zh) 用于治疗gm1神经节苷脂贮积症及其它病症的组合物和方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190614

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201112

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230106

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231127

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240223

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240223

End annual number: 3

Start annual number: 1

PG1601 Publication of registration